Introduction
============

Colorectal cancer (CRC) is one of the most common malignant tumors of the digestive tract in the world, and it is seriously endangering the health of humans. In recent years, the incidence of CRC showed an increasing trend and onset age is becoming increasingly younger ([@b1-ol-0-0-9611]). At present, surgical resection is the main treatment of CRC ([@b2-ol-0-0-9611]). However, due to differences in genotypes among different individuals, the incidence of drug resistance during chemotherapy increases significantly ([@b3-ol-0-0-9611]). Therefore, how to achieve personalized treatment of CRC under the guidance of precision medical treatment has been the focus of treatment in recent years.

Studies have shown that changes in molecular pathways are involved in the development of CRC tumors, of which microsatellite instability (MSI) and chromosomal instability (CIN) play the most important roles ([@b4-ol-0-0-9611]). MSI is the change of DNA genome sequence caused by mismatch repair gene mutation during DNA replication. It plays an important role in the regulation of various tumors, and CRC is one of the malignant tumors with a high incidence of MSI ([@b5-ol-0-0-9611]). It has been reported that \>90% of CRCs have a high degree of MSI ([@b6-ol-0-0-9611]). CIN is related to a variety of signal transduction pathways, of which the epidermal growth factor receptor (EGFR)-mediated signaling pathway plays an important role ([@b7-ol-0-0-9611]). Activation of the EGFR signal transduction pathway can regulate the phosphorylation of downstream signaling pathways, thereby promoting cell proliferation ([@b8-ol-0-0-9611]). *RAS* proto-oncogene family includes *KRAS, HRAS*, and *NRAS*, of which the *KRAS* gene has the highest mutation rate in CRC disease and can be as high as 45% ([@b9-ol-0-0-9611]). KRAS is an important component of the downstream pathway of the EGFR signaling pathway, and its mutation can lead to activation of the RAS/RAF/MAPK signaling pathway and loss of EGFR regulation ([@b10-ol-0-0-9611]). Therefore, outcomes of clinical use of EGFR drugs targeting *KRAS* gene mutations in CRC patients are extremely poor. In this study, PCR-Sanger sequencing and immunohistochemical methods were used to detect RAS gene mutations and MSI status in paraffin sections of patients with stage III CRC and to analyze the correlation with clinical parameters. Our study provided theoretical basis for personalized treatment for clinical CRC.

Patients and methods
====================

### Patient data

Tissues were collected from 180 patients who were diagnosed as stage III CRC in the Department of Gastrointestinal Surgery of the Fourth Hospital of Hebei Medical University (Shijiazhuang, China). All tissue specimens were fixed with 10% formaldehyde and stored as paraffin blocks. These patients included 104 males (57.78%) and 76 females (42.22%), and age ranged from 26 to 81 years, with an average age of 54.38+17.32 years. Inclusion criteria: i) all patients were treated with surgery and excluded from chemotherapy, radiotherapy, biological therapy, and other special treatment methods; ⅱ) patients pathologically diagnosed with stage III CRC; ⅲ) excluded from other intestinal diseases or other parts of the original tumor; and ⅳ) all the patients and their families were informed, and signed informed consent. In this study, the clinical and pathological grade of tumors were determined according to the standards proposed by the Union for International Cancer Control (UICC) in 2010 ([@b11-ol-0-0-9611]).

The study was approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University. Signed informed consents were obtained from the patients or the guardians.

### Detection of gene mutation

DNA was extracted from CRC paraffin blocks using a DNA FFPE Tissue kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer\'s instructions. PCR (Thermo Fisher Scientific, Inc.) reactions were performed to amplify DNA. All primer sequences are listed in [Table I](#tI-ol-0-0-9611){ref-type="table"}. Primers were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China). PCR reaction conditions were: 95°C for 10 min, followed by 40 cycles of 95°C for 30 sec, 50°C for 30 sec and 70°C for 1 min, and 70°C for 10 min. After purification of PCR products, Sanger sequencing of KRAS, NRAS and HRAS in the RAS family was performed using the ABI 3730×l sequencer (Sangon Biotech Co., Ltd.), and the sequencing results were analyzed.

### Immunohistochemistry

Immunohistochemistry was used to detect the expression of MLH1, MSH2, MSH6 and PMS2. CRC tissue blocks were used to prepare tissue sections with a thickness of 4 µm, which were fixed on glass slide, and then baked at 65°C for 2 h. After dewaxing and hydration, immunohistochemical SP was performed. All antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Tissue sections were incubated with primary mouse anti-human MLH1 (dilution, 1:200; cat. no. sc-56160), MSH2 (dilution, 1:250; cat. no. sc-56163), MSH6 (dilution, 1:100; cat. no. 137015), and PMS2 (dilution, 1:300; cat. no. sc-137015) monoclonal antibodies overnight at 4°C, followed by incubation with goat anti-mouse secondary polyclonal antibody (dilution, 1:100; cat. no. sc-2005) at 37°C for 1 h. DAB color development and hematoxylin counterstaining were performed. PBS was used instead of the primary antibody to serve as a negative control. Positive sections were used as positive controls.

### Determination of the results

Six visual fields were randomly selected under a 400-fold microscope (Olympus, Tokyo, Japan), and the results were judged by percentage of positive cells and depth of coloration. i) Scoring according to depth of coloration: negative was 0 points, light yellow was 1 point, brown-yellow score was 2 points, and brown score was 3 points. ⅱ) Scoring according to the percentage of positive cells: 0--30% was 1 point, 30--70% was 2 points, and 70--100% was 3 points. Product of the two scores ≥3 points was positive, otherwise it was negative. MSI result was determined as: positive expression of the above four proteins in CRC patients was defined as microsatellite stability (MSS). Negative expression of one of the proteins was defined as low degree of microsatellite instability (MSI-L). The presence of negative expression of two or more proteins was defined as high degree of microsatellite instability (MSI-H) ([@b12-ol-0-0-9611]).

### Statistical analysis

Statistical analysis was performed using the SPSS 22.0 statistical analysis software (IBM Corp., Armonk, NY, USA). Measurement data was recorded as mean ± SD Count data were recorded as rates and processed using Chi-square test to investigate the relationship between RAS gene mutations, MSI status, and CRC clinicopathological parameters. P\<0.05 indicates a difference with statistical significance ([Table I](#tI-ol-0-0-9611){ref-type="table"}).

Results
=======

### RAS gene mutation in stage III CRC patients

Analysis of 180 cases of phase III CRC tissues revealed that RAS mutation rate was 51.11% (92/180), of which KRAS and NRAS gene mutation rates were 48.33% (87/180) and 2.78% (5/180), respectively. HRAS mutation was not detected. The number of exon 2, 3 and 4 mutations in *KRAS* gene was 78 (89.66%), 2 (2.30%), and 7 (8.05%), respectively. Mutation rate of p.G12D in codon 12 of exon 2 in *KRAS* gene was the highest (31/87, 35.63%). Mutation rate of p.G12D in codon 12 of exon 2 in *NRAS* gene was the highest (2/5, 40%) ([Table II](#tII-ol-0-0-9611){ref-type="table"}).

### MSI status of patients with stage III CRC

Immunohistochemical detection of 180 cases of CRC tissues revealed that MLH1 protein positive expression was observed in 168 cases (93.33%) and negative expression in 12 cases (6.67%). MSH2 protein positive expression was observed in 154 cases (85.56%), and negative expression in 26 cases (14.44%). MSH6 protein was positively expressed in 151 cases (83.89%) and negatively expressed in 29 cases (16.11%). PMS2 protein was positively expressed in 148 cases (82.22%) and negatively expressed in 32 cases (17.78%). There were 148 cases of MSS status (82.22%), 22 cases of MSI-L status (12.22%), and 10 cases of MSI-H status (5.56%). In MSI-L and MSI-H status, MLH1 protein negative expression was the dominant (18/32, 56.25%). [Fig. 1](#f1-ol-0-0-9611){ref-type="fig"} shows the immunohistochemical staining of MSS.

### Relationship between RAS gene mutation and clinicopathological parameters of patients with stage III CRC

This study investigated the relationship between RAS gene mutations and clinicopathological parameters in stage III CRC patients and found that the mutation rate of *KRAS* gene in the right colon was 65.82%, which was significantly higher than that of the left colon and rectum (p\<0.05). Mutation rate in N2b phase was 81.48%, which was significantly higher than that in N2a and N1 phases (p\<0.01). NRAS gene mutation was not correlated with age, sex, lymph node metastasis, tumor site, depth of invasion, or pathological stage of CRC patients (p\>0.05) ([Table III](#tIII-ol-0-0-9611){ref-type="table"}).

### Relationship between MSI status and clinicopathological parameters of patients with stage III CRC

This study investigated the relationship between MSI status and clinicopathological parameters of patients with stage III CRC. Results showed that MSI-H was observed in 9 cases (6.82%) in patients with ≥50 years of age, which was significantly higher than that of CRC patients \<50 years (1 case, 2.08%, p\<0.05). The ratios of MSI-H in N1, N2a, and N2b phases were 1.75, 12.82, and 1.11%, respectively, and significant differences were found among them (p\<0.05) ([Table IV](#tIV-ol-0-0-9611){ref-type="table"}).

### Correlation between MSI status and RAS gene mutation in stage III CRC patients

Results of this study revealed that mutation rate of *KRAS* gene in MSI-H status of stage III CRC patients was 60% (6/10), which was significantly higher than that in MSI-L/MSS (47.65%, 81/170, p\<0.05). However, there was no significant difference in NRAS gene mutation rate among MSI-H, MSI-L/MSS status (p\>0.05) ([Table V](#tV-ol-0-0-9611){ref-type="table"}).

Discussion
==========

CRCs lack obvious symptoms and most patients are diagnosed with tumor metastasis, which is a major challenge of clinical treatment. Realization of disease molecular typing in individuals with tumors can help identify the biological characteristics of the tumor and clarify its pathogenesis ([@b13-ol-0-0-9611]). The three main molecular properties of CRC are CIN, MSI and CpG island methylation ([@b14-ol-0-0-9611]). The most important EGFR signal transduction pathway in CIN plays an important role in malignant transformation of tumors. Studies have shown that high expression of level EGFR in tumor tissue of malignant tumors promotes tumor cell invasion and metastasis ([@b15-ol-0-0-9611]). *KRAS, NRAS* and *HRAS* genes in RAS family are important downstream components of the EGFR signaling pathway. Studies have shown that mutations in *KRAS* gene cause conformational changes in KRAS protein that reduce its ability to bind to GDP. The binding of KRAS protein to GDP activates KRAS protein, ultimately activating downstream proliferative signaling pathways and promoting tumor cell growth ([@b16-ol-0-0-9611]). Therefore, the 2010 NCCN guidelines clearly stated that CRC patients should be tested for KRAS gene mutation rates to guide the clinical application of anti-EGFR signaling pathway drugs ([@b17-ol-0-0-9611]). MSI is another molecular characteristic of CRC, and its detection has become increasingly popular in the diagnosis of CRC. Mismatch repair genes encode MLH1, MSH2, PMS2, and MSH6 proteins to identify replication errors during DNA replication. DNA polymerases cleave the erroneously-replicated fragments, and DNA ligases cleave both ends of the excised fragments, so as to achieve correct DNA replication ([@b18-ol-0-0-9611]). Microsatellites are small DNA fragments in the human genome. Microsatellites are repeated sequences and error rate is high during replication. However, when the mismatch repair gene is mutated, the encoded protein cannot be expressed, and DNA erroneous replication cannot be corrected, eventually resulting in the production of MSI ([@b19-ol-0-0-9611]). Therefore, this study explored the correlation between RAS gene mutations, MSI status and the occurrence and development of CRC, so as to provide theoretical basis for individualized treatment of CRC patients.

In this study, tissue paraffin specimens from 180 patients with stage III CRC were examined. Results showed that the RAS mutation rate was 51.11% (92/180) and KRAS and NRAS gene mutation rate was 48.33% (87/180) and 2.78% (5/180), respectively. It has been reported that KRAS gene mutation rate in CRC patients is 35--45% ([@b20-ol-0-0-9611]), which is generally consistent with the results of our study. Ye *et al* ([@b21-ol-0-0-9611]) investigated the CRC of Chinese population and found that the mutation rate of *KRAS* gene was 37.9%, which was slightly lower than the results of our study. The possible explanation is they only included the 12th codon. In this study, codons 12 and 13 in exon 2 were both detected. Results showed that the number of exon 2, 3 and 4 mutations in KRAS mutations was 78 cases (89.66%), 2 cases (2.30%), 7 cases (8.05%), respectively. Mutation rate of p.G12D in codon 12 of exon 2 was the highest (35.63%, 31/87), which was in agreement with that reported by Ye *et al* ([@b21-ol-0-0-9611]). Mutation rate of p.G13D in codon 13 was 21.84% (19/87), which was lower than the mutation rate of codon 12. This result is consistent with that of Omidifar *et al* ([@b22-ol-0-0-9611]). HRAS mutation was not detected, which was consistent with the results of previous studies ([@b23-ol-0-0-9611]). This study further analyzed the correlation between KRAS and NRAS mutations and the clinicopathological parameters of phase III CRC and found that mutation rate of *KRAS* gene in right colon was 65.82%, which was significantly higher than that in left colon and rectum (p\<0.05). Mutation rate in N2b phase was 81.48%, which was significantly higher than that in N2a and N1 phases (p\<0.01), but there was no correlation with other pathological parameters. Studies have shown that the age of patients with KRAS and CRC and the degree of tumor differentiation are closely observed ([@b24-ol-0-0-9611],[@b25-ol-0-0-9611]). An explanation of the different results may be the differences in the survey population. It has been reported that NRAS gene mutations are associated with low expression of c-MET, and NRAS gene mutations are more likely to occur in elderly patients with malignant melanoma ([@b26-ol-0-0-9611]). In this study we found that NRAS gene mutations were not associated with age, sex, lymph node metastasis, tumor location, depth of invasion, and pathological stage of patients with CRC, possibly due to the fact that mutation rate of NRAS in CRC is significantly lower than that of KRAS ([@b27-ol-0-0-9611]). In addition, the sample size of our study was small and biased results cannot be avoided.

In this study, immunohistochemistry was used to detect phase III CRC tissue paraffin sections. There were 148 cases (82.22%) of MSS status, 22 cases (12.22%) of MSI-L status, 10 cases (5.56%) of MSI-H status, and MKH1 protein negative expression was dominant in MSI-L and MSI-H status (18/32, 56.25%), indicating that patients with stage III CRC are mainly MSS. Fleming *et al* ([@b28-ol-0-0-9611]) analyzed 128 patients with malignant rectal cancer and found that patients with MSI-H mostly showed poor differentiation, lymph node infiltration, and high degree of tissue heterogeneity, and MSI-H mostly occurred in female patients and right semi-colon. Correlation analysis showed that MSI-H is closely related to the pathological stage of CRC, and it mostly occurs in elderly patients aged ≥50 years. The reason for the discrepancy in the analysis is that this study only selected patients with stage III CRC as the study subjects, and Fleming *et al* ([@b28-ol-0-0-9611]) selected patients with stage II and III CRC as study subjects. Finally, the relationship between RAS gene mutation and MSI was analyzed. It was found that the mutation rate of *KRAS* gene in MSI-H status of stage III CRC patients was 60% (6/10), which was significantly higher than that in MSI-L/MSS (47.65%, 81/170). Mutation rate of *NRAS* gene was not correlated with MSI. Ogura *et al* ([@b26-ol-0-0-9611]) found that patients with MSI-L tumors were more likely to have NRAS mutations than KRAS mutations, possibly due to the different subjects included in that study.

In summary, RAS gene mutation and MSI status are involved in the occurrence and development of stage III CRC, and detection of these indexes is of great significance to the individual treatment of CRC in the clinic.
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###### 

RAS gene amplification primer sequences and PCR product length.

  Name       Forward primer             Reverse primer           Fragment length (bp)
  ---------- -------------------------- ------------------------ ----------------------
  KRAS                                                           
    Exon 2   CCAGACTGTGTTTCTCCCTTC      TTTAAACCCACCTATAATGGTG     92
    Exon 3   CTTGGATATTCTCGACACAGCA     TCCCTCATTGCACTGTACTCCT   131
    Exon 4   TGATTTTGCAGAAAACAGAT       GACACAAAACAGGCTCAGGA     120
  NRAS                                                           
    Exon 2   ATGACTGAGTACAAACTGGTC      CTCTATGGTGGGATCATATTG    128
    Exon 3   AAACAAGTGGTTATAGATGGT      CACAGAGGAAGCCTTCGCCT       97
    Exon 4   TTGGCCCCATTTAGAAACTTCTGT   TCATCTTGGGCTCTTGTGCCA      93
  HRAS                                                           
    Exon 2   TCACGCACCAACGTGTAGAA       CTTCGAGATGGCCAGAGTCC     204

###### 

Incidence of KRAS and NRAS mutations \[n (%)\].

  Gene exon   Gene mutations   n (%)
  ----------- ---------------- ------------
  KRAS                         
    Exon 2    p.G12D           31 (35.63)
              p.G12V           14 (16.09)
              p.G12A           5 (5.75)
              p.G12C           4 (4.60)
              p.G12S           4 (4.60)
              p.G12R           1 (1.15)
              p.G13D           19 (21.84)
    Exon 3    p.A59T           1 (1.15)
              p.Q61H           1 (1.15)
    Exon 4    p.A146T          4 (4.60)
              p.A146V          1 (1.15)
              Others           2 (2.30)
    Total                      87 (48.33)
  NRAS                         
    Exon 2    p.G12D           2 (40.00)
    Exon 3    p.A18T           1 (20.00)
              p.Q61L           1 (20.00)
              p.Q61R           1 (20.00)
    Total                      5 (2.78)

###### 

Relationship between RAS gene mutations and clinicopathological parameters of patients with stage III CRC \[n (%)\].

                                 KRAS          NRAS                                                                                                                 
  ----------------------- ------ ------------- ------------- ---------- ------- -------------- ---------- ---------- ------- ------------- ------------- ---------- -------
  Sex                                                                                                                                                               
    Male                  104    47 (45.19)    57 (54.81)      11.382   0.492   101 (97.12)    3 (2.88)     21.843   0.281   49 (47.12)    55 (52.88)      39.221   0.183
    Female                  76   46 (60.53)    30 (39.47)                         74 (97.37)   2 (2.63)                      70 (92.11)    6 (7.89)                 
  Age (years)                                                                                                                                                       
    \<50                    48   31 (64.58)    17 (35.42)      31.940   0.192     47 (97.92)   1 (2.08)     14.483   0.381   35 (72.92)    13 (27.08)      17.281   0.415
    ≥50                   132    62 (46.97)    70 (53.03)                       128 (96.97)    4 (3.03)                      84 (63.64)    48 (36.36)               
  Lymph node metastasis                                                                                                                                             
    No                    107    64 (59.81)    43 (40.19)      79.171   0.091   104 (97.20)    3 (2.80)     49.173   0.121   67 (62.62)    40 (37.38)      56.331   0.105
    Yes                     73   29 (39.73)    44 (60.27)                         71 (97.26)   2 (2.74)                      52 (71.23)    21 (28.77)               
  Tumor site                                                                                                                                                        
    Right colon             79   27 (34.18)    52 (65.82)    124.218    0.038     77 (97.47)   2 (2.53)     44.711   0.184   33 (41.77)    46 (58.23)      83.191   0.092
    Left colon              15     8 (53.33)     7 (46.67)                        14 (93.33)   1 (6.67)                        9 (60.00)     6 (40.00)              
    Rectum                  86   58 (67.44)    28 (32.56)                         84 (97.67)   2 (2.33)                      77 (89.53)      9 (10.47)              
  Infiltration depth                                                                                                                                                
    T1                      2      1 (50.00)     1 (50.00)     20.911   0.294   0              2 (100)      46.831   0.128   0               2 (100.0)     12.011   0.493
    T2                      15     8 (53.33)     7 (46.67)                        14 (93.33)   1 (6.67)                        9 (60.00)     6 (40.00)              
    T3                    128    69 (53.91)    59 (46.09)                       127 (99.22)    1 (0.78)                      90 (70.31)    38 (29.69)               
    T4                      35   15 (42.86)    20 (57.14)                         34 (97.14)   1 (2.86)                      20 (57.14)    15 (42.86)               
  Pathological stage                                                                                                                                                
    N1                    114    73 (64.04)    41 (35.96)    214.281    0.003   111 (97.37)    3 (2.63)   101.382    0.069   84 (73.68)    30 (26.32)    177.264    0.012
    N2a                     39   15 (38.46)    24 (61.54)                         38 (97.44)   1 (2.56)                      21 (53.85)    18 (46.15)               
    N2b                     27     5 (18.52)   22 (81.48)                         26 (96.30)   1 (3.70)                      14 (51.85)    13 (48.15)               

###### 

Relationship between MSI status and clinicopathological parameters of patients with stage III CRC \[n (%)\].

  Pathological parameters   Cases   MSI-H         MSI-L/MSS      χ^2^       P-value
  ------------------------- ------- ------------- -------------- ---------- ---------
  Sex                                                                       
    Male                    104     7 (6.73)        97 (93.27)     13.281   0.381
    Female                    76    3 (3.95)        73 (96.05)              
  Age (years)                                                               
    \<50                      48    1 (2.08)        47 (97.92)     71.306   0.028
    ≥50                     132     9 (6.82)      123 (93.18)               
  Lymph node metastasis                                                     
    No                      107     6 (5.61)      101 (94.39)      41.811   0.128
    Yes                       73    4 (5.48)        69 (94.52)              
  Tumor site                                                                
    Right colon               79    7 (8.86)        72 (91.14)     59.441   0.091
    Left colon                15    1 (6.67)        14 (93.33)              
    Rectum                    86    2 (2.33)        84 (97.67)              
  Infiltration depth                                                        
    T1                        2     0               2 (100.0)      32.912   0.294
    T2                        15    1 (6.67)        14 (93.33)              
    T3                      128     7 (5.47)      121 (94.53)               
    T4                        35    2 (5.71)        33 (94.29)              
  Pathological stage                                                        
    N1                      114     2 (1.75)      112 (98.25)    101.221    0.012
    N2a                       39      5 (12.82)     34 (87.18)              
    N2b                       27    3 (1.11)        24 (88.89)              

MSI, microsatellite instability; CRC, colorectal cancer; MSI-H, high degree of microsatellite instability; MSI-L, low degree of microsatellite instability; MSS, microsatellite stability.

###### 

Correlation between MSI status and RAS gene mutation in patients with stage III CRC \[n (%)\].

                     KRAS          NRAS                                                              
  ----------- ------ ------------- ------------- --------- ------- ------------- ---------- -------- -------
  MSI-H         10     4 (40.00)     6 (60.00)   104.281   0.011     9 (90.00)   1 (1.00)   14.921   0.385
  MSI-L/MSS   170    89 (52.35)    81 (47.65)                      166 (97.65)   4 (2.35)            

MSI, microsatellite instability; CRC, colorectal cancer; MSI-H, high degree of microsatellite instability; MSI-L, low degree of microsatellite instability; MSS, microsatellite stability.
